Apellis Pharmaceuticals, Inc. APLS NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

48/100

1/7 Pass

SharesGrow Intrinsic Value

Apellis Pharmaceuticals, Inc. (APLS) has 20 détenteurs institutionnels et initiés connus enregistrés. Le plus grand détenteur est Morningside Venture Investments Ltd avec 12,806,342 actions. Parmi les autres détenteurs notables Deschatelets Pascal et Francois Cedric.

Au cours des 12 derniers mois, les initiés ont effectué 86 transactions sur APLS l'action — 32 achats (d'une valeur de $19.26M) et 39 ventes (d'une valeur de $10.82M). Les ventes d'initiés ont dépassé les achats durant cette période.

APLS Participations des Initiés

Principal Actionnaire

Morningside Venture Investments Ltd

12,806,342 actions

Achats (12 mois)

$19.26M valeur

Ventes (12 mois)

$10.82M valeur

Activité de transactions (12 mois)

Acheter 37%

Vendre 45%

Principaux actionnaires initiés

#	Nom	Rôle	Actions détenues	Dernière déclaration	Taille relative
1	Morningside Venture Investments Ltd	10 Percent Owner	12,806,342	2021-11-18	100%
2	Deschatelets Pascal	Chief Scientific Officer	1,177,222	2026-01-30	9%
3	Francois Cedric	Chief Executive Officer	372,815	2026-03-13	3%
4	Sullivan Timothy Eugene	Chief Financial Officer	152,041	2026-01-30	1%
5	Watson David O.	General Counsel	144,517	2026-01-30	1%
6	Boucher Kelley	Chief People Officer	127,804	2026-01-30	1%
7	Nicholson Nur	Chief Technical Officer	116,338	2026-01-30	1%
8	Delong Mark Jeffrey	Chief Business & Strat Officer	114,591	2026-02-13	1%
9	Meltzer Leslie	Chief Research and Development	107,024	2026-01-30	1%
10	Grossi Federico	Chief Medical Officer	94,884	2023-01-09	1%
11	Baumal Caroline	Chief Medical Officer	86,527	2026-01-23	1%
12	Townsend Adam J.	Chief Commercial Officer	84,050	2025-01-30	1%
13	Lewis Karen	Chief People Officer	70,251	2025-01-30	1%
14	Chopas James George	VP/chief Accounting Officer	65,955	2026-01-30	1%
15	Eisele Jeffrey	Chief Development Officer	55,312	2025-01-30	0%
16	Scheibler Lukas	Chief Research Officer	39,391	2023-12-05	0%
17	Brown Victoria L.	Program Team Lead	23,556	2023-01-24	0%
18	Walbert Keli	Director	14,684	2026-01-05	0%
19	Wheeler Craig A	Director	14,684	2026-01-05	0%
20	Machiels Alec	Director	14,684	2026-01-05	0%

Transactions récentes (12 derniers mois)

Date	Nom	Rôle	Type	Actions	Prix	Valeur
2026-03-31	Biogen Inc.	Other: See Footnotes	Inconnu	-	-	-
2026-03-11	Francois Cedric	Chief Executive Officer	Don (Reçu)	64,869	-	-
2026-03-02	Dolsten Mikael	Director	Inconnu	-	-	-
2026-02-27	Dolsten Mikael	Director	Attribution de RSU	14,312	-	-
2026-02-11	Delong Mark Jeffrey	Chief Business & Strat Officer	Vente Informative	368	$22.15	$8.15K
2026-02-03	Francois Cedric	Chief Executive Officer	Exercice d'Options (Vente)	8,840	$3.76	$33.24K
2026-01-28	Meltzer Leslie	Chief Research and Development	Attribution de RSU	45,220	-	-
2026-01-28	Boucher Kelley	Chief People Officer	Attribution de RSU	30,146	-	-
2026-01-28	Delong Mark Jeffrey	Chief Business & Strat Officer	Attribution de RSU	36,606	-	-
2026-01-28	Chopas James George	VP/chief Accounting Officer	Attribution de RSU	16,150	-	-
2026-01-28	Nicholson Nur	Chief Technical Officer	Attribution de RSU	45,220	-	-
2026-01-28	Sullivan Timothy Eugene	Chief Financial Officer	Attribution de RSU	58,140	-	-
2026-01-28	Francois Cedric	Chief Executive Officer	Attribution de RSU	195,952	-	-
2026-01-28	Deschatelets Pascal	Chief Scientific Officer	Attribution de RSU	25,840	-	-
2026-01-28	Watson David O.	General Counsel	Attribution de RSU	55,986	-	-
2026-01-22	Baumal Caroline	Chief Medical Officer	Vente Informative	2,797	$21.77	$60.88K
2026-01-22	Delong Mark Jeffrey	Chief Business & Strat Officer	Vente Informative	3,371	$21.77	$73.37K
2026-01-22	Chopas James George	VP/chief Accounting Officer	Vente Informative	2,064	$21.77	$44.92K
2026-01-22	Nicholson Nur	Chief Technical Officer	Vente Informative	7,725	$21.77	$168.14K
2026-01-22	Sullivan Timothy Eugene	Chief Financial Officer	Vente Informative	10,287	$21.77	$223.9K
2026-01-22	Francois Cedric	Chief Executive Officer	Vente Informative	27,192	$21.77	$591.84K
2026-01-22	Deschatelets Pascal	Chief Scientific Officer	Vente Informative	5,928	$21.77	$129.03K
2026-01-22	Watson David O.	General Counsel	Vente Informative	7,832	$21.77	$170.47K
2026-01-20	Baumal Caroline	Chief Medical Officer	Vente Informative	1,882	$19.79	$37.25K
2026-01-20	Delong Mark Jeffrey	Chief Business & Strat Officer	Vente Informative	1,334	$19.79	$26.4K